secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001601485-25-000114
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio publishes Phase 1 ELI-002 data in Nature Medicine: OS 28.94 months, 77% risk reduction
--------------------------------------------------------------------------------

- At 19.7 mo median follow-up, median OS increased to 28.94 months from 16.33 months in Phase 1 AMPLIFY-201.
- Above-threshold T cell responses gave 77% reduction in death risk (HR 0.23) and 88% reduction in relapse risk (HR 0.12).
- 84% (21/25) of patients had tumor biomarker responses; 24% (6/25) achieved complete biomarker clearance.
- Final event-driven DFS analysis for Phase 2 AMPLIFY-7P study of ELI-002 7P in PDAC anticipated Q4 2025.
- ELI-002 was well tolerated; no dose-limiting toxicities or ≥Grade 3 treatment-related adverse events observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000114/0001601485-25-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000114/angn-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001601485-25-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer